C , cause proximal spinal muscular atrophy (SMA), an autosomal recessive disorder that results in loss of motor neurons. SMN is found in the cytoplasm and nucleus. The nuclear form is located in structures termed gems. Using a panel of anti-SMN antibodies, we demonstrate that the SMN protein is expressed from both the SMN T and SMN C genes. Western blot analysis of fibroblasts from SMA patients with various clinical severities of SMA showed a moderate reduction in the amount of SMN protein, particularly in type I (most severe) patients. Immunocytochemical analysis of SMA patient fibroblasts indicates a significant reduction in the number of gems in type I SMA patients and a correlation of the number of gems with clinical severity. This correlation to phenotype using primary fibroblasts may serve as a useful diagnostic tool in an easily accessible tissue. SMN is expressed at high levels in brain, kidney and liver, moderate levels in skeletal and cardiac muscle, and low levels in fibroblasts and lymphocytes. In SMA patients, the SMN level was moderately reduced in muscle and lymphoblasts. In contrast, SMN was expressed at high levels in spinal cord from normals and non-SMA disease controls, but was reduced 100-fold in spinal cord from type I patients. The marked reduction of SMN in type I SMA spinal cords is consistent with the features of this motor neuron disease. We suggest that disruption of SMN T in type I patients results in loss of SMN from motor neurons, resulting in the degeneration of these neurons.
INTRODUCTION
Proximal spinal muscular atrophy (SMA) is an autosomal recessive disorder that results in destruction of the α motor neurons in the anterior horn of the spinal cord. SMA has an estimated incidence of 1 in 10 000 live births with a carrier frequency of 1 in 40 (1) . The childhood SMAs can be classified into three groups based on age of onset and clinical course (2) . Type I SMA is the most severe form with onset before the age of six months and death occurring within the first two years of life. Type II SMA is intermediate in severity with onset of symptoms before 18 months of age and patients never gaining the ability to walk. Individuals with type III SMA, the mildest form that typically presents after the age of 18 months, are able to stand and walk.
All three forms of proximal SMA have been mapped by linkage analysis to chromosome 5q12 (3) (4) (5) (6) (7) (8) (9) (10) (11) in a region that contains multiple copies of both genes and markers (12) (13) (14) (15) (16) (17) (18) . Analysis of these multicopy markers showed that specific alleles associate with SMA (18) (19) (20) (21) , the loss of a copy of the marker in ∼50% of severe SMA cases (20) (21) , and deletions of all copies of the marker on some SMA chromosomes (15, 21) . Three cDNAs that detect deletions in SMA patients were simultaneously reported (16) (17) (18) . Two of these cDNAs, neuronal apoptosis inhibitory protein (NAIP) and XS2G3, detect the same deletion in 50% of type I SMA cases, and appear to mark the extent of deletion (16, 17, (21) (22) . The third cDNA, survival motor neuron (SMN), is encoded by two nearly identical genes, telomeric SMN (SMN T ) Figure 1 . Antibodies to SMN. HeLa cell protein was solubilized and run on a 12% polyacrylamide gel and blotted. The western blot was cut into strips and each strip was probed with a separate antibody raised against SMN or the secondary antibodies as negative controls. (A) Crude antibodies: N-terminal (SMN-NT) and C-terminal (SMN-CT) polyclonal peptide antibodies and a chicken polyclonal Ab (SMN-C3) all recognize the same 38 kDa band detected by mAb 2B1 (41) . The label above the strip denotes the primary antibody used on that particular strip. (B) Affinity purified SMN-NT and SMN-CT antibodies recognize only SMN in HeLa cells. 2_αRb, donkey anti-rabbit-HRP antibody secondary antibody alone; 2_αCh, donkey anti-chicken-HRP F(ab′) 2 antibody; 2_αMs, sheep anti-mouse-HRP antibody.
and centromeric SMN (SMN C ). These genes can be distinguished from one another by base pair changes in exons 7 and 8 (18, 24) . The SMN T gene is not detectable in 95% of SMA cases due either to gene deletion or conversion of the sequences in the SMN T gene to those of the SMN C gene (18, (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . Conversion events predominate in mild SMA chromosomes whereas deletion of SMN T is associated with severe SMA chromosomes (33) (34) (35) . Cases of SMA that have detectable SMN T have been identified, and were shown to possess several small mutations in SMN T . These mutations include deletions that disrupt splicing of exon 7 (18), deletion of 4 or 5 bp in exon 3 (32, 36) , an 11 bp duplication in exon 6 (37) , and five different missense mutations in exons 6 and 7 (18, 35, (38) (39) (40) . Dosage analysis of the SMN T gene indicates that the majority of these small mutation cases are compound heterozygotes and that current methods have detected ∼75% of non-deletion/conversion mutations (35, 40) . These data clearly indicate that SMN T is the SMA gene and that the region encoded by exons 6 and 7 is important for normal function of the SMN T gene product in motor neurons.
Recent studies have demonstrated that antibodies against SMN detect a 38 kDa protein that is localized in the cytoplasm and the nucleus (41) . Nuclear SMN is found in a structure named gems for 'Gemini of the coiled bodies' (41). These novel structures, which are detected by anti-SMN antibodies, are ∼0.1-1 µm in size, and appear to be intimately associated with the nuclear coiled bodies. Coiled bodies are subnuclear structures believed to have a role in mRNA metabolism. The gems appear to interact directly with the coiled bodies and undergo similar changes in response to environmental and metabolic conditions of the cell (41) . This suggests that gems function in concert with the coiled bodies, and may also share a role in RNA processing (41) . At present, there are no other markers for the gem structures and their function is unknown.
The effect of the loss of the SMN T gene on the levels of SMN protein in SMA patients has not been reported. In this paper, we use a panel of antibodies to analyze the SMN protein in SMA patient tissue. We show that both the SMN T and SMN C genes produce SMN protein. Secondly, the number of gems as detected by SMN antibodies correlates with the phenotype of the patient. Thirdly, type II patients have significantly more gems as detected with SMN antibodies than type I patients even though the copy number of the SMN C and SMN T genes are equivalent in both patients. This indicates that not all SMN C genes are functionally equivalent. Finally, we show that the amount of SMN protein is reduced in tissues of SMA patients. Type I SMA patients show a 100-fold reduction of SMN in spinal cord. Therefore, the disruption of the SMN T gene in type I SMA patients causes a reduction of the SMN protein in the motor neurons and results in motor neuron degeneration.
RESULTS

Anti-SMN antibodies
The SMN gene is ubiquitously expressed. We, therefore, examined the SMN protein in lymphoblasts, fibroblasts, spinal cord and muscle of SMA and non-SMA individuals. We developed a chicken polyclonal antibody to SMN (SMN-C3) by injection of a His-tagged SMN bacterial fusion protein that lacked exon 5 into chickens. We also used a rabbit antibody raised against peptide sequences (amino acids 270-289 of SMN) in the C-terminal domain (SMN-CT) (Strasswimmer et al., manuscript in preparation), and a previously reported monoclonal antibody 2B1 (41) for analysis of SMN. Figure 1 shows a western blot of HeLa cells demonstrating that all three antibodies detect the same 38 kDa protein. A fourth antibody, SMN-NT, raised against peptide sequences (amino acids 10-29 of SMN) from the N-terminal domain (Strasswimmer et al., manuscript in preparation), is also shown in Figure 1 . We found that the SMN-C3 and SMN-CT were the most effective at detecting SMN protein on western blots. The monoclonal antibody 2B1 and affinity purified SMN-NT were effective for immunocytochemistry studies. 
Immunocytochemical analysis of gems in SMA fibroblasts
We investigated the number of gems as detected by anti-SMN antibodies in fibroblasts. In primary fibroblasts, the gem number was dependent on the confluency of the cultures, such that confluent cells have a low number of gems and semi-confluent cells have a higher number of gems (data not shown). The gem status in all cells was therefore assayed in the semi-confluent state. All cells were seeded out at a constant density. After a period of 24 h, the cells were fixed, permeabilized and immunostained with anti-SMN antibodies. Figure 3 shows the typical staining pattern observed for normal, carrier, type I, type II and type III SMA fibroblasts. The number of gems is greatly reduced in type I SMA fibroblasts. In order to more accurately correlate gem number to SMA type, we counted the gems in more than 500 nuclei in each of these cell lines. In order to avoid unintentional bias, the investigator was blinded to the clinical phenotype of the patient from whom the fibroblasts were derived. The results are summarized in Table 1 . Normal patients with two copies of SMN T had more gems than the type I SMA carrier indicating that the number of copies of SMN T can influence the number of gems. However, the copy number of SMN C did not appear to influence the gem number as indicated by the carrier 3814 who had four copies of SMN C and individual 96-2865, a type II SMA individual, who had three copies of SMN C but showed gem numbers in concordance with their phenotype ( Fig 3) . This would indicate that not all SMN C genes are equivalent and that the SMN C genes in type II and III individuals produce sufficient amounts of the correct SMN isoform to assemble gems, whereas SMN C genes in type I SMA patients do not. This suggests that some SMN C genes can modify the pathophysiology of SMA.
Western analysis of spinal cord and other tissues
The level of SMN protein in different tissues was investigated by quantitative western blot analysis. In adult tissues the level of SMN expression is high in spinal cord, kidney, liver and brain tissue, lower in skeletal and cardiac muscle, and considerably lower in fibroblasts and lymphocytes (Fig. 4) . The expression of SMN in lymphocytes from a type III patient with a point mutation (35) , and a phenotypically normal patient (6376 I-1) without detectable SMN T (31) was also examined. The differences in expression of SMN normalized to β-tubulin is not significant (Fig. 4B ). In muscle (Fig. 4C) , the reduction of SMN levels was similar to that observed for the fibroblasts with a reduction in tissue or cells derived from type I patients. Additionally, SMN expression in lymphoblastoid cell lines was examined. The normalized levels of expression in lymphoblasts between the type I patients and the unaffected carriers or normal controls were marginally altered (Fig. 4D) . Lastly, we examined the SMN protein levels in spinal cord from SMA and disease controls. The disease controls included four patients with disorders manifesting motor neuron loss. These included two patients (3206, 3210, Table 2 ) diagnosed with Amyotrophic Lateral Sclerosis (ALS), and two patients (3201, 3204) with a neurological disease similar to SMA. Affected patients and disease controls were tested by dosage analysis for the SMN gene copy number. The results are shown in Table 2 . All of the type I SMA samples were deleted for SMN T , whereas the disease controls are not. One sample was originally referred to as a type I SMA patient (3204) and another as a type II SMA patient (3201). However, dosage analysis clearly indicates that these individuals have two copies of SMN T and, therefore, these samples are unlikely to be 5q SMA cases (35) . Figure 5 shows the western blot data for these patients using the antibodies SMN-C3 and SMN-CT. The SMN protein was found to be reduced at least 100-fold in the spinal cord of the SMA patients but not the disease controls (Fig. 4 and Table 2 ). Interestingly, antibody SMN-CT showed decreased affinity for SMN from patient 89-208. The SMN-CT antibody recognizes the epitope encoded by exon 7 (Strasswimmer, personal communication). Exon 7 only adds ∼2 kDa to the molecular weight of SMN, which if spliced out would not be resolved. Therefore, one possible explanation for this, is that the cells in the spinal cord of 89-208 are expressing SMN isoforms that have spliced out exon 7.
The blot was stripped and reprobed with a polyclonal antibody that detects choline acetyltransferase (ChAT): a motor neuron specific marker in spinal cord. As seen in Figure 5 , SMN, ChAT, and β-tubulin are comparable in non-SMA disease controls indicating that motor neurons are present in these individuals, and are expressing SMN. In SMA patients, however, ChAT and β-tubulin are expressed at essentially normal levels, but SMN is significantly reduced. This strongly suggests that the reduction in SMN expression is not simply the result of motor neuron loss.
DISCUSSION
The SMN gene and isoforms
The SMN T gene has been shown by mutation analysis to be the SMA determining gene (18, (32) (33) (34) (35) (36) (37) (38) (39) (40) . In humans, the SMN cDNA is encoded by two genes, SMN T and SMN C (18) . These genes can be distinguished at the DNA and RNA level by nucleotide changes in exons 7 and 8 that do not alter the encoded amino acids (18) . Alternative splicing has been shown to occur in the SMN genes in humans. The majority of transcripts (∼90%) from the SMN T gene are full length. The remainder (∼10%) are missing exon 5 (18, 37, 42) . The SMN C gene produces all of the SMN isoforms, including transcripts without exon 5, transcripts without exon 7, transcripts lacking both exons 5 and 7, as well as full length SMN. The full length transcript accounts for only 20-30% of the total transcripts from the SMN C gene (18, 37, 42) . Therefore, one effect of the loss of the SMN T gene is the reduction in the total amount of full length transcript. However, the amount of full length transcript could vary in a particular patient due to the variable copy number of SMN C (35) . The importance of the full length SMN transcript is also implicated by studies of the SMN homologue in mouse. The murine genome contains one copy of the SMN gene per chromosome, which does not undergo alternative splicing, and therefore only produces the full length SMN isoform (43) (44) . Gennarelli et al. (42) determined the levels of SMN isoforms in muscle tissue from patients of varying phenotypic severity, but did not observe any differences between the phenotypic groups. However, the isoform levels were measured relative to each other and did not take into account the variant copy number or expression levels of SMN C genes, because no mRNA external to SMN was used to calibrate the level of various SMN isoforms.
SMN C genes are not functionally equivalent
In this paper, we demonstrate that both the SMN C and SMN T genes produce protein and the status of each contributes to disease severity. Nearly all SMA patients used in this study had no detectable SMN T genes regardless of their clinical SMA phenotype. The only exception to this is the type III patient shown in Figure 4D . As seen in Table 1 , patients with types I and II SMA can have an identical copy number of SMN C . However, in all cases type II SMA patients clearly had many more detectable gems than type I patients. Gems, which lie adjacent to the coiled bodies in the nucleus, are the punctate structures detected by SMN antibodies. Gems are believed to have a role in RNA processing (41) . As seen in Table 1 , type II patients produce many more gems than type I SMA patients who have the identical SMN C copy number. This suggests that not all SMN C genes are equivalent. That is, some SMN C genes can produce sufficient SMN for gem formation, albeit at a reduced number.
The exact difference between these SMN C alleles is not known. The most likely explanation is that in type II SMA patients, one of the SMN C loci is generated by gene (sequence) conversion of an SMN T gene to an SMN C gene. Expression of the appropriate form of SMN protein from this converted SMN T gene is reduced, but still sufficient for the formation of gems. In type I SMA patients, however, the loss of SMN T is most often due to deletion. The SMN C gene remaining in the type I patients is not capable of expressing the appropriate form, or amounts of SMN for the formation of gems (33, 34) . Indeed, previous studies using markers that flank the SMN region indicate that deletions of SMN T are specific to type I chromosomes and conversions of SMN T genes to SMN C genes predominate in typeII/III chromosomes (20) (21) (22) 33, 34) . Analysis of SMN C copy number distribution in normals and SMA carriers indicates a gain of one SMN C gene in type II/III SMA chromosomes. The gain of SMN C genes in mild SMA cases is consistent with gene conversion predominating in mild chromosomes (34, 35) . Furthermore, Campbell et al. (33) provide physical evidence that conversion and not deletion has occurred in mild SMA chromosomes. Chimeric genes have also been identified in SMA patients where exon 8 of the SMN T gene is joined to exon 7 of the SMN C gene (25, 28, 29) . This can occur by one of two general mechanisms: first, deletion of the region between the SMN genes and fusion of the 5′ end of SMN C with the 3′ end of SMN T or second, conversion of the sequences in the SMN T genes to those in the SMN C gene. The former would be a severe allele because there is a deletion of the majority of the SMN T gene (27) (28) (29) .
It has been suggested that the copy number of SMN C could modify the phenotypic severity (18, 30) . However, the correlation of SMN C copy number to severity is not absolute. We have shown, by immunocytochemical and western blot analysis, that type II patients with exactly the same SMN C copy number as a type I patient produce considerably more gems and SMN. This strongly suggests that there are differences between SMN C genes in type I and II patients. One explanation is that there are critical sequences 5′ of exon 7 which are not present or are mutated in SMN C genes in type I patients. For instance, conversion events that occur in type II SMA would not exchange the entire gene but just the 3′ end, retaining the critical sequences in the 5′ end of the SMN gene. Sequence analysis of the SMN C and SMN T genes is critical to resolve whether any difference between these two genes exists in the 5′ region. Therefore, differences between the SMN C genes present in a severe chromosome and a mild chromosome remain to be resolved. Based on the presence of a modifying SMN C gene and a non-modifying SMN C gene, we have suggested a modification of the previous models of SMA (20, 21, 29, 33) . In this model we suggest that no copies of modifying SMN C genes occur in type I SMA, one copy occurs in type II SMA and two in type III SMA (34) .
SMN expression in various tissues
SMA is a disorder that affects motor neurons. The level of expression in other adult tissues is variable, with high levels of expression present in the brain, liver and kidney, moderate levels in cardiac and skeletal muscle, and the lowest levels in fibroblasts and lymphocytes. In type I patients, a mutation in SMN T has a modest effect on the level of expression in fibroblasts and skeletal muscle, and yet the number of detectable gems in fibroblasts is an indicator of the severity of the disease. That is, a low number of gems correlates with the severe form of SMA and higher numbers correlate with milder forms of SMA. Gems are nuclear structures of ∼0.1-1 µm in size that lie adjacent to the coiled bodies (41) . Gems have been suggested to have a role in RNA metabolism (41) . The loss of SMN from the gems in SMA has a catastrophic effect on the motor neuron cell, but exactly what metabolic pathways are disrupted is unknown.
The tissue that shows the most significant alteration in the expression of SMN is the spinal cord. We have shown here that the levels of SMN are normally high in spinal cord but are reduced 100-fold in samples from type I SMA patients. The loss of SMN in spinal cord critically affects the motor neurons, and may explain the specificity of this disease for the α motor neurons. This effect could be due to the exquisite sensitivity of motor neurons to the loss of SMN or that the SMN T gene contains an element lacking in SMN C that allows expression in motor neurons throughout life, including the time when the neuron makes contact with the muscle. Detailed analysis of the elements controlling SMN expression will be required to resolve this question.
MATERIALS AND METHODS
Patient materials
Patients were diagnosed with spinal muscular atrophy using the criteria outlined by the International SMA Consortium. Lymphocytes were obtained from blood samples by fractionation in Lymphocyte Separation Medium (Organon Teknika). Muscle biopsies were originally obtained for diagnostic purposes. Tissue including spinal cord material was obtained at post-mortem from a total of four type I SMA patients, two ALS patients, one patient with Multiple Sclerosis (MS) and two patients who were originally referred as SMA, however analysis of SMN T gene copy number showed two copies of the SMN T gene. The SMN T gene is not detectable in 95% of 5q SMA cases. Therefore, according to Hardy-Weinberg equilibrium, virtually all the remaining 5q SMA individuals should have a heterozygous deletion (35) . Both of these cases have two copies of the SMN T ; we have not detected any other alterations in the SMN T gene from these patients. Hence, these two patients most likely have an unclassified motor neuron disease resembling SMA. For the remaining patients, the diagnosis of SMA was confirmed by demonstrating the absence of SMN T using the method described by McAndrew et al. (35) . Primary fibroblasts from type I (four cell lines), type II (eight lines), type III (one line), and one normal (96-2842) were obtained and grown in culture using standard protocols.
Immunocytochemistry
Fibroblasts were plated at a density of 10 5 on gelatinized coverslips in a 150 mm plate. The subconfluent cultures were obtained by growing the cells for 24 h after plating. The confluent cultures were prepared as above, except cells were not fixed until the cells had reached confluency by visual inspection. The cells were fixed for 7 min in ice cold 50% methanol-50% acetone. Fixation by paraformaldehyde/sucrose methods showed similar results (Strasswimmer et al., unpublished observations). The coverslips were then air dried for 30 min and stored at -70_C until used. The cells on the coverslips were rehydrated with phosphate buffered saline (PBS) for 5 min, and then blocked with 1× BLOCK [1% fetal bovine serum, 1% horse serum, 0.1% bovine serum albumin (BSA) in PBS] for 30 min. The 2B1 monoclonal antibody (41) was diluted 1:500 in the 1× BLOCK solution and applied to the coverslips for 1 h in a humidity chamber. The coverslips were extensively washed with PBS (6 × 5 min) and the secondary antibody (goat anti-mouse TRITC conjugate, Sigma Chemical) diluted 1:300 in 1× BLOCK was applied. After 1 h, the coverslips were again extensively washed with PBS. The coverslips were mounted on Superfrost slides (Fisher Scientific) using DAPI II (Vysis) diluted 1:3 in antifade solution (Vector Research). The cells were then examined on a Zeiss microscope equipped 63× objective and a dual band pass filter set suitable for DAPI/TRITC fluorescence.
Western blot analysis
Tissue samples and cell pellets were dissolved in blending buffer (10% sodium dodecyl sulfate (SDS), 62.5 mM Tris pH 6.8, 5 mM ethylenediaminetetraacetic acid (EDTA), 1 mM phenylmethylsulfonylfluoride (PMSF) (added fresh). The protein concentration of the samples were determined using BCA kit (Pierce, Rockford IL) according to the manufacturer's instructions. An equal volume of sample buffer (62.5 mM Tris pH 6.8, 10% glycerol, 10% 2-mercaptoethanol, 0.4 mg Bromophenol Blue) was added to the remaining supernatant. The samples were boiled for 2 min and stored at -20_C until use. Samples were electrophoresed on a 12% polyacrylamide gel, transferred to Immobilon-P (Millipore) in a Hoeffer TE50 transblot apparatus at 7 V/cm constant voltage for 1.5 h in 192 mM glycine, 25 mM Tris, 0.1% SDS, 20% methanol. The Immobilon was blocked for 1 h at room temperature in 5% instant milk, 1% BSA in 25 mM Tris pH 7.5, 500 mM NaCl (TBS). The primary antibody was diluted 1:1000 SMN-NT, SMN-CT (Strasswimmer et al.) , anti-β-tubulin (Amersham), or 1:10 000 SMN-C3 in 1% milk, 0.2% BSA in TBS containing 0.2% Tween-20 (TTBS), and placed on the blot for 1 h. The blot was washed four times 10 min each with TTBS. The secondary antibody was diluted into 1% milk, 0.2% BSA in TTBS as above. The sheep anti-mouse and donkey anti-rabbit HRP conjugated antibodies (Amersham) were used at 1:1000 dilution. A donkey anti-chicken F(ab′) 2 antibody (Jackson Immunoresearch) was diluted 1:20 000. For the spinal cord immunoblots, the diluted secondary antibodies were preadsorbed against a human spinal cord acetone powder preparation (45) . The blots were incubated with the secondary antibodies for 1 h at room temperature and washed as above. After a final 15 min wash with TBS, the blot was visualized using ECL chemiluminescent reagent (Amersham) or Pierce Ultra stable reagent according to the manufacturer's instructions. The blots were exposed to Kodak X-OMAT LS film for the detection of the chemiluminescent emissions. Blots were stripped and reprobed according to the manufacturer's protocols.
Western blot quantitation
The levels of SMN were determined by scanning western blots on an AGFA Arcus II flat bed scanner set for the highest quality. The images were imported into BioMax 1D image analysis software (Kodak) which was calibrated with a T-14 optical density scale.
The level of SMN relative to β-tubulin was determined by dividing the scanned density of SMN bands by the scanned density of β-tubulin for each lane. These ratios were then normalized to that of the control sample.
Fusion protein and antibody preparation
An SMN expression construct for the isolation of fusion protein was assembled by cloning a cDNA lacking exon 5 into the pRSETC vector (Invitrogen). The removal of the proline rich sequence encoded by exon 5 of SMN was performed in order to enhance the expression of the bacterial fusion protein. The fusion protein was purified under denaturing conditions on the TALON resin (Clontech) according to the manufacturer's instructions. Injections of the affinity purified fusion protein into chickens was carried out by Cocalico Biologicals (Lancaster, PA) using standard protocols (45) . Titers of the crude serum were determined according to standard methods (45) . Antibodies were purified by incubating the antibodies with nitrocellulose squares saturated with purified fusion protein. After 1 h, the antibody was eluted in 500 µl of 20 mM glycine pH 2.4, 1 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA). The supernatant was neutralized with 125 µl of 1 M Tris pH 8. The titer was determined using standard methods (45) .
SMN T and SMN C copy-number assay
The SMN T and SMN C copy number was determined from genomic DNA using the assay described in McAndrew et al. (35) .
